Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma.

ABSTRACT:

Background

Treatment personalization via tumor molecular testing holds promise for improving outcomes for patients with pediatric low-grade glioma (PLGG). We evaluate the health economic impact of employing tumor molecular testing to guide treatment for patients diagnosed with PLGG, particularly the avoidance of radiation therapy (RT) for patients with BRAF-fusion.

Methods

We performed a model-based cost-utility analysis comparing two strategies: molecular testing to determine BRAF fusion status at diagnosis against no molecular testing. We developed a microsimulation to model the lifetime health and cost outcomes (in quality-adjusted life years (QALYs) and 2018 CAD, respectively) for a simulated cohort of 100,000 patients newly diagnosed with PLGG after their initial surger

SUBMITTER: Rios JD 

PROVIDER: S-EPMC8722113 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature